Clinical and demographic details of patients treated with the anti-IL-12/IL-23 antibody ustekinumab
| Patient no. | Age | Sex | Type of IBD | Type of skin lesions | CDAI before ustekinumab | CDAI at week 16* | Change of skin lesions |
|---|---|---|---|---|---|---|---|
| 2 | 28 | M | CD | Palmoplantar pustular psoriasis, psoriasis capillitii | N/A | 84 | ++ |
| 3 | 27 | F | CD | Diffuse alopecia | 0 (complete remission) | 0 (complete remission) | +++ |
| 9 | 22 | M | CD | Palmoplantar psoriasis, alopecia | 62 | 101 | ++ |
| 11 | 20 | M | CD | Guttate psoriasis, psoriasis capillitii | 69 | 69† | ++ |
| 12 | 30 | F | CD | Pustular palmoplantar psoriasis | 49 | 183‡ | ++ |
| 14 | 61 | M | CD | Psoriasis capillitii, features of psoriasis and LE | 0 (complete remission) | 50§ | +++ |
| 20 | 40 | F | CD | Palmoplantar psoriasis, psoriasis capillitii | 313 | 214¶ | ++ |
| A | 48 | F | CD | Palmoplantar psoriasis with nail involvement | 279 | 103 | +++ |
| B | 31 | F | CD | Psoriasis inversa | 341 | 348 | ++ |
Severity of Crohn's disease was evaluated by using the Crohn's Disease Activity Index (CDAI). Clinical improvement of psoriasiform skin lesion was determined by an independent dermatologist using a semiquantitative score (− worsened; 0 no change; + slight improvement; ++ marked improvement; +++ healed).
*CDAI was calculated at week 16 after two ustekinumab injections (on the day of the third ustekinumab injection but before the third ustekinumab injection).
†The patient is a stoma carrier. Therefore, the CDAI of this patient is shown without including the score for stool frequency into the total CDAI score.
‡At week 16, the patient was diagnosed with Campylobacter jejuni infection.
§Three ustekinumab injections (45 mg at week 0, 45 mg at week 4, 90 mg at week 10).
¶Prior to week 16, the patient was treated with prednisolone due to a disease flare (20 mg for 1 week and then reducing the dose by 2.5 mg per week).
CD, Crohn's disease; f, female; IBD, inflammatory bowel disease; m, male.